<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Rizatriptan: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Rizatriptan: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Rizatriptan: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11032" href="/d/html/11032.html" rel="external">see "Rizatriptan: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="17059" href="/d/html/17059.html" rel="external">see "Rizatriptan: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F218997"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Maxalt;</li>
<li>Maxalt-MLT</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868182"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACCEL-Rizatriptan ODT;</li>
<li>ACT Rizatriptan;</li>
<li>AG-Rizatriptan ODT;</li>
<li>APO-Rizatriptan;</li>
<li>APO-Rizatriptan RPD [DSC];</li>
<li>Auro-Rizatriptan [DSC];</li>
<li>CCP-Rizatriptan ODT [DSC];</li>
<li>DOM-Rizatriptan RDT;</li>
<li>JAMP-Rizatriptan;</li>
<li>JAMP-Rizatriptan IR [DSC];</li>
<li>JAMP-Rizatriptan ODT;</li>
<li>MAR-Rizatriptan;</li>
<li>MAR-Rizatriptan ODT;</li>
<li>Maxalt;</li>
<li>Maxalt RPD;</li>
<li>MYLAN-Rizatriptan ODT;</li>
<li>NAT-Rizatriptan ODT;</li>
<li>NRA-Rizatriptan ODT;</li>
<li>PMS-Rizatriptan RDT;</li>
<li>SANDOZ Rizatriptan ODT;</li>
<li>TEVA-Rizatriptan ODT</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F219026"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antimigraine Agent;</li>
<li>
                        Serotonin 5-HT<sub>1B, 1D</sub> Receptor Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F219001"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d36d256f-8d0c-47cc-acaf-2f0f3747bed4">Migraine, moderate to severe, acute treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine,</b>
<b>moderate to severe, acute treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Do <b>not</b> use within 24 hours of an ergotamine preparation or a different triptan. Limit use to &lt;10 days per month to avoid medication-overuse headache. Administration early in the course of a migraine attack, at the first sign of pain, may improve response to treatment. A large initial dose may be more effective than multiple smaller doses. When attack is complicated by severe nausea or vomiting, a nonoral medication may be more effective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10403069','lexi-content-ref-34160823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10403069','lexi-content-ref-34160823'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 5 to 10 mg (orally disintegrating tablet, tablet) or 10 mg (oral film) as a single dose; if symptoms persist or return, may repeat dose after ≥2 hours. The manufacturer’s labeling recommends a maximum daily dose of 30 mg per 24 hours; however, some experts recommend a maximum of 20 mg per 24 hours; efficacy data are not available for doses exceeding 20 mg in a 24-hour period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23968886','lexi-content-ref-9595867','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23968886','lexi-content-ref-9595867','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991267"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, the AUC was 44% greater in patients on hemodialysis.</p></div>
<div class="block doha drugH1Div" id="F50988499"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, plasma concentrations are increased by 30% in patients with moderate hepatic dysfunction.</p></div>
<div class="block doe drugH1Div" id="F219002"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F14292543"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="17059" href="/d/html/17059.html" rel="external">see "Rizatriptan: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="94e2a3ee-a6a7-47a4-9a9e-1102ebb9cf5e">Migraine, acute treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, acute treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: Oral: <b>Note:</b> Safety and efficacy of multiple rizatriptan doses in a 24-hour period has not been established for pediatric patients.</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;40 kg: 5 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">≥40 kg: 10 mg as a single dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51159917"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, the AUC was 44% greater in patients on hemodialysis.</p></div>
<div class="block dohp drugH1Div" id="F51159918"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, plasma concentrations are increased by 30% in patients with moderate hepatic dysfunction.</p></div>
<div class="block adr drugH1Div" id="F218968"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (≤3%), flushing (&gt;1%), palpitations (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness (4% to 9%), drowsiness (4% to 8%), fatigue (adults: 4% to 7%; children: &gt;1%), paresthesia (3% to 4%), pain (3%), feeling of heaviness (≤2%), headache (≤2%), euphoria (&gt;1%), hypoesthesia (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (4% to 6%), xerostomia (3%), sore throat (≤2%), abdominal distress (children: &gt;1%), diarrhea (&gt;1%), vomiting (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Weakness (4% to 7%), jaw pain (≤2%), jaw pressure (≤2%), jaw tightness (≤2%), neck pain (≤2%), neck pressure (≤2%), neck tightness (≤2%), tremor (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngeal edema (≤2%), pressure on pharynx (≤2%), dyspnea (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abdominal distention, abnormal gait, agitation, anaphylaxis, anaphylactoid reaction, angina pectoris, angioedema, ataxia (children), auditory impairment (children), blurred vision, bradycardia, cardiac arrhythmia, cold extremities, confusion, diaphoresis, dysgeusia, dyspepsia, edema, erythema, facial edema, hallucination (children), hot flash, hypertensive crisis, increased blood pressure (diastolic/systolic), insomnia, ischemic heart disease, lack of concentration (children), memory impairment, muscle rigidity, muscle spasm, myalgia, myocardial infarction, pharyngeal edema, pruritus, seizure, skin rash, swelling of eye, syncope, tachycardia, tinnitus, tongue edema, toxic epidermal necrolysis, urticaria, vasospasm, vertigo, wheezing</p></div>
<div class="block coi drugH1Div" id="F218980"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to rizatriptan or any component of the formulation; ischemic coronary artery disease (eg, angina pectoris, history of myocardial infarction, or documented silent ischemia) or other significant cardiovascular disease; coronary artery vasospasm (including Prinzmetal angina); history of stroke or transient ischemic attack; peripheral vascular disease; ischemic bowel disease; uncontrolled hypertension; hemiplegic migraine or migraine with brainstem aura; during or within 2 weeks of monoamine oxidase inhibitor use; during or within 24 hours of treatment with another 5-HT<sub>1</sub> agonist, or an ergotamine-containing or ergot-type medication (eg, methysergide, dihydroergotamine); concurrent use with propranolol (oral film only); Wolff-Parkinson-White Syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders (oral film only).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Valvular heart disease or cardiac arrhythmias (especially tachycardias); ophthalmoplegic migraine; severe hepatic impairment.</p></div>
<div class="block war drugH1Div" id="F218965"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac events: Coronary artery vasospasm, transient ischemia, myocardial infarction, ventricular tachycardia/fibrillation, cardiac arrest, and death have been reported with 5-HT<sub>1</sub> agonist administration. Patients who experience sensations of chest pain/pressure/tightness or symptoms suggestive of angina following dosing should be evaluated for coronary artery disease or Prinzmetal's angina before receiving additional doses; if dosing is resumed and similar symptoms recur, monitor with ECG.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cerebrovascular events: Cerebral/subarachnoid hemorrhage and stroke have been reported with 5-HT<sub>1</sub> agonist administration. Use is contraindicated in patients with a history of stroke or transient ischemic attack</p>
<p style="text-indent:-2em;margin-left:4em;">• Elevated blood pressure: Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension.</p>
<p style="text-indent:-2em;margin-left:4em;">• Headaches: Acute migraine agents (eg, triptans, opioids, ergotamine, or a combination of the agents) used for 10 or more days per month may lead to worsening of headaches (medication overuse headache); withdrawal treatment may be necessary in the setting of overuse.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vasospasm-related events: Peripheral vascular ischemia and colonic ischemia, gastrointestinal ischemia/infarction, splenic infarction, and Raynaud syndrome have been reported with 5-HT<sub>1</sub> agonist.</p>
<p style="text-indent:-2em;margin-left:4em;">• Visual effects: Rarely, partial vision loss and blindness (transient and permanent) have been reported with 5-HT<sub>1</sub> agonist.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Coronary artery disease: Should not be given to patients who have risk factors for CAD (eg, hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, menopause, male &gt;40 years of age) without adequate cardiac evaluation. Patients with suspected CAD should have cardiovascular evaluation to rule out CAD before considering use; if cardiovascular evaluation is “satisfactory,” first dose should be given in the healthcare provider's office (consider ECG monitoring). Periodic evaluation of cardiovascular status should be done in all patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; drug clearance may be reduced leading to increased plasma concentrations.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in dialysis patients (systemic exposure is increased).</p>
<p style="text-indent:-4em;margin-left:4em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Serotonin syndrome: Symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may occur with concomitant proserotonergic drugs (ie, SSRIs/SNRIs or triptans) or agents which reduce rizatriptan's metabolism. Concurrent use of serotonin precursors (eg, tryptophan) is not recommended. If concomitant administration with SSRIs is warranted, monitor closely, especially at initiation and with dose increases.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylalanine: Orally disintegrating tablets contain phenylalanine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Only indicated for treatment of acute migraine; not for the prevention of migraines or the treatment of cluster headache. If a patient does not respond to the first dose, the diagnosis of migraine should be reconsidered.</p></div>
<div class="block prod-avail drugH1Div" id="F58081659"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">RizaFilm oral film: FDA approved April 2023; anticipated availability currently unknown.</p></div>
<div class="block foc drugH1Div" id="F218975"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Maxalt: 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Maxalt-MLT: 10 mg [contains aspartame; peppermint flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p></div>
<div class="block geq drugH1Div" id="F218961"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F218981"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (Maxalt-MLT Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $50.45</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (Rizatriptan Benzoate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $33.24 - $36.37</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $33.24 - $36.37</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Maxalt Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $50.45</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Rizatriptan Benzoate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $6.33 - $36.65</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $21.58 - $37.19</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868183"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Maxalt: 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Maxalt RPD: 5 mg, 10 mg [contains aspartame]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p></div>
<div class="block adm drugH1Div" id="F14292544"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> May be administered with or without food. For orally disintegrating tablets and oral film, patient should be instructed to place tablet/film on tongue and allow to dissolve; film will dissolve in ~2 minutes. Dissolved tablet/film will be swallowed with saliva.</p></div>
<div class="block admp drugH1Div" id="F52613827"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Orally disintegrating tablets (Maxalt-MLT®): Do not remove the blister from the pouch until ready to use; blister pouch should be opened by peeling back (not pushing through foil) and with dry hands; place tablet on the tongue to dissolve; do not crush, break, or chew; additional liquids are not necessary.</p></div>
<div class="block use drugH1Div" id="F218976"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Migraine, moderate to severe, acute treatment: </b>Acute treatment of migraine with or without aura in adults and pediatric patients ≥6 years of age (orally disintegrating tablet, tablet) or in adults and pediatric patients ≥12 years of age weighing ≥40 kg (oral film).</p></div>
<div class="block cyt drugH1Div" id="F13300011"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F218969"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: May enhance the adverse/toxic effect of Serotonin 5-HT1D Receptor Agonists (Triptans). Management: Consider alternatives to this combination when possible. If combined, monitor for increased bromocriptine and triptan toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Droxidopa: Serotonin 5-HT1D Receptor Agonists (Triptans) may enhance the hypertensive effect of Droxidopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): Serotonin 5-HT1D Receptor Agonists (Triptans) may enhance the vasoconstricting effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: Serotonin 5-HT1D Receptor Agonists (Triptans) may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Monoamine Oxidase Inhibitors may increase the serum concentration of Serotonin 5-HT1D Receptor Agonists (Triptans). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: May increase the serum concentration of Rizatriptan. Management: Adults: limit rizatriptan dose to 5 mg (max of 3 doses per 24 hrs). Pediatric patients: if weight is 40 kg or more, limit rizatriptan to a single 5 mg dose per 24 hrs; do not combine if weight less than 40 kg. Rizatriptan oral film is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Serotonin 5-HT1D Receptor Agonists (Triptans) may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the vasoconstricting effect of other Serotonin 5-HT1D Receptor Agonists (Triptans).<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F218982"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">A registry has been established to monitor outcomes of women exposed to rizatriptan during pregnancy. Preliminary data from the pregnancy registry (prospectively collected from 65 live births 1998-2004) does not show an increased risk of congenital malformations in comparison to the general population (Fiore 2005). Additional information collected through 2018 has not shown a pattern of birth defects or other adverse outcomes; however, data is limited and loss to follow-up is significant. Outcome data following maternal use of rizatriptan during pregnancy from other studies are also available (Källén 2011; Nezvalová-Henriksen 2010; Nezvalová-Henriksen 2012; Nezvalová-Henriksen 2013; Spielmann 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Triptans relieve migraine pain by selectively binding to serotonin receptors, resulting in vasoconstriction of cranial arteries. Although the effects on uterine blood flow have not been evaluated, one case report suggests excessive use of a triptan may cause placental hypoperfusion (ACOG 2022; Viard 2021).</p>
<p style="text-indent:0em;margin-top:2em;">The risk of preeclampsia may be increased in patients with migraine (ACOG 2022). Treatment for migraine headaches in pregnant patients should be individualized (AHS [Ailani 2021]). Triptans are not the preferred initial treatment for acute migraine headache in pregnant patients (ACOG 2022). Until additional data are available, rizatriptan is not the preferred triptan when first-line therapy is ineffective. Triptans should be avoided in pregnant patients with cardiac disease or hypertension (ACOG 2022; CHS [Worthington 2013]).</p></div>
<div class="block brc drugH1Div" id="F20548419"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Rizatriptan is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of 5-HT<sub>1B/1D</sub> agonists (triptans) in breast milk is available from a study of 19 lactating women (6 weeks to 30 months postpartum) treated for migraine headaches. During the study, infants were fed previously expressed breast milk. Breast milk was sampled prior to and at intervals up to 24 hours after the dose in 5 patients taking rizatriptan 10 mg. Using the average breast milk concentration observed, authors of the study calculated the estimated exposure of rizatriptan to the breastfed infant to be 0.4 to 2.2 mcg/kg/day, providing a relative infant dose (RID) of 0.3% to 1.4% based on the weight-adjusted maternal dose. Using the maximum breast milk concentration, the RID of rizatriptan was calculated to be 1.7% to 9.7%. In 3 samples, rizatriptan was not detectable in breast milk 24 hours after the dose. A large interindividual variability among breast milk concentrations was found with all the triptans in the study, even when considering dose and dosage form (Amundsen 2021). In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">Treatment for migraine headaches in lactating patients should be individualized (AHS [Ailani 2021]). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Withholding breastfeeding for 24 hours after the maternal dose will minimize infant exposure via breast milk. The decision to withhold breastfeeding following a dose of rizatriptan should be part of a shared decision-making process (ACOG 2022).</p></div>
<div class="block dic drugH1Div" id="F218983"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain phenylalanine.</p></div>
<div class="block mop drugH1Div" id="F218973"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Headache severity, signs/symptoms suggestive of angina; perform a cardiovascular evaluation in triptan-naive patients who have multiple cardiovascular risk factors (eg, increased age, diabetes, hypertension, smoking, obesity, strong family history of coronary artery disease), monitor ECG with first dose in patients with multiple cardiovascular risk factors who have a negative cardiovascular evaluation, and consider periodic cardiovascular evaluation in such patients if they are intermittent long-term users.</p></div>
<div class="block pha drugH1Div" id="F218964"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Selective agonist for serotonin (5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors) in cranial arteries; causes vasoconstriction and reduces sterile inflammation associated with antidromic neuronal transmission correlating with relief of migraine</p></div>
<div class="block phk drugH1Div" id="F218979"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Exposures following a single dose in pediatric patients ≥6 years were similar to those observed following a single dose in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Most patients have response to treatment within 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Complete.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Females: 110 L; Males 140 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 14%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Via monoamine oxidase-A; forms metabolites; significant first-pass metabolism.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Orally disintegrating tablet, tablet: ~45%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Orally disintegrating tablet, tablet: 2 to 3 hours; oral film: 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Tablet: 1 to 1.5 hours; Orally disintegrating tablet: 1.6 to 2.5 hours; Oral film: 1.4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (82%, 14% as unchanged drug); feces (12%).</p></div>
<div class="block phksp drugH1Div" id="F51159819"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In patients with CrCl 10 to 60 mL/min/1.73 m<sup>2</sup>, the AUC<sub>0-∞</sub> of rizatriptan was not significantly different. In hemodialysis patients (CrCl less than 2 mL/min/1.73 m<sup>2</sup>), the AUC for rizatriptan was approximately 44% greater than that in patients with healthy renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Plasma concentrations of rizatriptan were approximately 30%greater in patients with moderate hepatic insufficiency.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Rizatriptan pharmacokinetics in healthy elderly nonmigraineur volunteers (65 to 77 y of age) were similar to those in younger nonmigraineur volunteers (18 to 45 y of age).</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: AUC is approximately 30% higher and C<sub>max</sub> is 11% higher in women than in men.</p>
<p style="text-indent:-2em;margin-left:2em;">Race/ethnicity: Pharmacokinetic data revealed no significant differences between black and white subjects.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F218984"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Maxalt</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Maxalt</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Maxalt</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo rizatriptan | Chemmart rizatriptan | Maxalt | Maxatan | Rixalt | Rizatriptan | Rizatriptan an odt</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Rizamig | Rizat</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Rizatriptan</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Rizatriptan</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Maxalt</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Rizatriptan mepha oro | Rizatriptan Sandoz | Rizatriptan spirig hc</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Maxalt</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ou li ting | Rizatriptan monobenzoate</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Maxalt</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Rizatriptan | Rizatriptan AbZ | Rizatriptan AL | Rizatriptan aurobindo | Rizatriptan Glenmark | Rizatriptan Heumann | Rizatriptan Hexal | Rizatriptan Hormosan | Rizatriptan neuraxpharm | Rizatriptan ratiopharm | Rizatriptan stada | Rizatriptan tillomed</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Maxalt</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Maxalt rpd</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Migrapain | Migriza | Migtriptan</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Rizatriptan apotex | Rizatriptan aurobindo | Rizatriptan flas cinfa | Rizatriptan flas kern | Rizatriptan flas qualigen | Rizatriptan flas tecnigen | Rizatriptan max msd | Rizatriptan max mylan | Rizatriptan normon | Rizatriptan ratiopharm | Rizatriptan Sandoz | Rizatriptan stada | Rizatriptan teva | Rizatriptan tillomed | Rizatriptan vir | Rizatriptan viso farmaceutica</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Rizastad | Rizatriptan actavis | Rizatriptan ratiopharm | Rizatriptan Sandoz | Rizatriptan stada</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Maxaltlyo | Rizatriptan actavis | Rizatriptan biogaran | Rizatriptan eg | Rizatriptan mylan | Rizatriptan Sandoz | Rizatriptan teva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Rizatriptan | Rizatriptan neuraxpharm | Rizatriptan teva</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Rizatriptan/Genepharm</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Maxalt</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Calvinia | Maxalt | Maxalt rapidisc</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Maxalt</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Rizalt</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Maxtan | Receptan | Ritza | Rizact | Rizatan | Rizatrip | Rizora</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Addariz | Ecuhead | Maxalt | Rizaliv | Rizatriptan actavis | Rizatriptan aurobindo | Rizatriptan doc | Rizatriptan eg | Rizatriptan germed | Rizatriptan mylan | Rizatriptan Sandoz | Rizatriptan tecnigen | Rizatriptan teva | Rizatriptan zentiva | Trizadol | Trizadol RPD</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Rizatriptan od amel | Rizatriptan od pfizer | Rizatriptan od tck | Rizatriptan od towa</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Rizact | Rizat</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Maxalt</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Maxalt</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Rizatriptan</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Maxaltlyo | Rizact</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Rizatriptan</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Calvinia | Maxalt</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Migrix</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Maxalt</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Rizatriptan | Rizatriptan actavis | Rizatriptan aurobindo | Rizatriptan CF | Rizatriptan Glenmark | Rizatriptan mylan | Rizatriptan Sandoz</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Maxalt lingua | Rizatriptan AL | Rizatriptan aurobindo</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Maxalt melt | Rizamelt | Rizatriptan</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Maxalt</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Maxalt</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Rizatriptan | Rizatriptan benzoate odt | Rizatriptan odt</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Maxalt</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Orziban</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Maxalt Mlt | Migon | Pms rizatriptan rdt | Rizatriptan</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Rizasmelt | Rizatriptan 2care4 | Rizatriptan abacus medicine | Rizatriptan actavis | Rizatriptan aurobindo | Rizatriptan Ebb | Rizatriptan Glenmark | Rizatriptan mylan | Rizatriptan orifarm | Rizatriptan Sandoz | Rizatriptan stada | Rizatriptan teva</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Maxalt</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Rizatriptan mylan | Rizatriptan Sandoz</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Maxalt</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Migoff | Rizatan</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Rizamigren | Rizatriptan | Rizoptan</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Maxalt</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Maxalt | Migrariz | Migrazan | Rizatriptan mylan | Sandoz rizatriptan</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-16943370">
<a name="16943370"></a>Ahonen K, Hämäläinen ML, Eerola M. et al, "A Randomized Trial of Rizatriptan in Migraine Attacks in Children," <i>Neurology</i>, 2006, 67(7):1135-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/16943370/pubmed" id="16943370" target="_blank">16943370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10403069">
<a name="10403069"></a>Ahrens SP, Farmer MV, Williams DL, et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group. <i>Cephalalgia</i>. 1999;19(5):525-530. doi:10.1046/j.1468-2982.1999.019005525.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/10403069/pubmed" id="10403069" target="_blank">10403069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34160823">
<a name="34160823"></a>Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. <i>Headache</i>. 2021;61(7):1021-1039. doi:10.1111/head.14153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/34160823/pubmed" id="34160823" target="_blank">34160823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576364">
<a name="35576364"></a>American College of Obstetricians and Gynecologists (ACOG). Headaches in pregnancy and postpartum: ACOG clinical practice guideline no. 3. <i>Obstet Gynecol</i>. 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/35576364/pubmed" id="35576364" target="_blank">35576364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33730376">
<a name="33730376"></a>Amundsen S, Nordeng H, Fuskevåg OM, Nordmo E, Sager G, Spigset O. Transfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding. <i>Basic Clin Pharmacol Toxicol</i>. 2021;128(6):795-804. doi:10.1111/bcpt.13579<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/33730376/pubmed" id="33730376" target="_blank">33730376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15784664">
<a name="15784664"></a>Boyer EW and Shannon M, “The Serotonin Syndrome,” <i>N Engl J Med</i>, 2005, 352(11):1112-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/15784664/pubmed" id="15784664" target="_blank">15784664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22823482">
<a name="22823482"></a>Da Silva AN and Tepper SJ, "Acute Treatment of Migraines," <i>CNS Drugs</i>, 2012, 26(10):823-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/22823482/pubmed" id="22823482" target="_blank">22823482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16109049">
<a name="16109049"></a>Fiore M, Shields KE, Santanello N, et al, "Exposure to Rizatriptan During Pregnancy: Post-Marketing Experience Up to 30 June 2004," <i>Cephalalgia</i>, 2005, 25(9):685-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/16109049/pubmed" id="16109049" target="_blank">16109049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21751829">
<a name="21751829"></a>Källén B, Nilsson E, and Otterblad Olausson P, "Delivery Outcome After Maternal Use of Drugs for Migraine: A Register Study in Sweden," <i>Drug Saf</i>, 2011, 34(8):691-703.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/21751829/pubmed" id="21751829" target="_blank">21751829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15623677">
<a name="15623677"></a>Lewis D, Ashwal S, Hershey A, et al, "Practice Parameter: Pharmacological Treatment of Migraine Headache in Children and Adolescents: Report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society," <i>Neurology</i>, 2004, 63(12):2215-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/15623677/pubmed" id="15623677" target="_blank">15623677</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Maxalt and Maxalt-MLT (rizatriptan) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; September 2020.</div>
</li>
<li>
<div class="reference">
                  Maxalt and Maxalt RPD (rizatriptan) [product information]. Kirkland, Quebec, Canada: Organon Canada Inc; May 2021.</div>
</li>
<li>
<div class="reference">
                  Maxalt tablet (rizatriptan) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; October 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22946832">
<a name="22946832"></a>Nezvalová-Henriksen K, Spigset O, and Nordeng HM, "Errata in 'Triptan Exposure During Pregnancy and the Risk of Major Congenital Malformations and Adverse Pregnancy Outcomes: Results From the Norwegian Mother and Child Sohort Study,'" <i>Headache</i>, 2012, 52(8):1319-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/22946832/pubmed" id="22946832" target="_blank">22946832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20132339">
<a name="20132339"></a>Nezvalová-Henriksen K, Spigset O, and Nordeng H, "Triptan Exposure During Pregnancy and the Risk of Major Congenital Malformations and Adverse Pregnancy Outcomes: Results From the Norwegian Mother and Child Cohort Study," <i>Headache</i>, 2010, 50(4):563-75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/20132339/pubmed" id="20132339" target="_blank">20132339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23884894">
<a name="23884894"></a>Nezvalová-Henriksen K, Spigset O, Nordeng H. Triptan safety during pregnancy: a Norwegian population registry study. <i>Eur J Epidemiol</i>. 2013;28(9):759-769.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/23884894/pubmed" id="23884894" target="_blank">23884894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rizafilm.1">
<a name="Rizafilm.1"></a>Rizafilm (rizatriptan) [prescribing information]. Saint-Laurent, Quebec, Canada: IntelGenx Corp; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-RizatriptanBenzoate.1">
<a name="RizatriptanBenzoate.1"></a>Rizatriptan Benzoate [prescribing information]. Princeton, NJ: Macleods Pharma USA Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28758416">
<a name="28758416"></a>Spielmann K, Kayser A, Beck E, Meister R, Schaefer C. Pregnancy outcome after anti-migraine triptan use: a prospective observational cohort study. <i>Cephalalgia</i>. 2018;38(6):1081-1092.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/28758416/pubmed" id="28758416" target="_blank">28758416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9595867">
<a name="9595867"></a>Teall J, Tuchman M, Cutler N, et al; Rizatriptan 022 Study Group. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. <i>Headache</i>. 1998;38(4):281-287. doi:10.1046/j.1526-4610.1998.3804281.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/9595867/pubmed" id="9595867" target="_blank">9595867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32886179">
<a name="32886179"></a>Viard D, Gérard A, Tahiri J, Tieulié N, Van Obberghen E, Drici MD. Triptan overuse during pregnancy: a possible cause of placental hypoperfusion. <i>Eur J Clin Pharmacol</i>. 2021;77(2):269-270. doi:10.1007/s00228-020-02991-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/32886179/pubmed" id="32886179" target="_blank">32886179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15447698">
<a name="15447698"></a>Visser WH, Winner P, Strohmaier K, et al, "Rizatriptan 5 mg for the Acute Treatment of Migraine in Adolescents: Results From a Double-Blind, Single-Attack Study and Two Open-Label, Multiple-Attack Studies," <i>Headache</i>, 2004, 44(9):891-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/15447698/pubmed" id="15447698" target="_blank">15447698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12005275">
<a name="12005275"></a>Winner P, Lewis D, Visser WH, et al, "Rizatriptan 5 mg for the Acute Treatment of Migraine in Adolescents: A Randomized, Double-Blind, Placebo-Controlled Study," <i>Headache</i>, 2002, 42(1):49-55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/12005275/pubmed" id="12005275" target="_blank">12005275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23968886">
<a name="23968886"></a>Worthington I, Pringsheim T, Gawel MJ, et al. Canadian Headache Society Guideline: acute drug therapy for migraine headache. <i>Can J Neurol Sci</i>. 2013;40(5)(suppl 3):S1-S80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rizatriptan-drug-information/abstract-text/23968886/pubmed" id="23968886" target="_blank">23968886</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10243 Version 393.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
